Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $12.10

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has received an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.10.

Several research analysts have weighed in on the company. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $7.00 to $12.00 in a research report on Monday, March 16th. Wedbush increased their price objective on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Guggenheim increased their price objective on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Cantor Fitzgerald increased their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th.

Insider Buying and Selling

In related news, SVP Marcia Belvin sold 31,492 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the transaction, the senior vice president owned 300,760 shares in the company, valued at approximately $1,930,879.20. This trade represents a 9.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christopher Ogden sold 19,323 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the transaction, the chief financial officer owned 296,948 shares in the company, valued at $1,906,406.16. The trade was a 6.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 191,063 shares of company stock worth $1,226,624 over the last three months. Company insiders own 6.60% of the company’s stock.

Institutional Trading of CytomX Therapeutics

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in CytomX Therapeutics by 1,064.3% during the first quarter. Bank of America Corp DE now owns 10,202,785 shares of the biotechnology company’s stock worth $47,953,000 after buying an additional 9,326,480 shares in the last quarter. Perceptive Advisors LLC grew its holdings in CytomX Therapeutics by 4.3% during the first quarter. Perceptive Advisors LLC now owns 10,098,824 shares of the biotechnology company’s stock worth $47,464,000 after buying an additional 418,639 shares in the last quarter. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics during the second quarter worth $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics in the second quarter worth $17,462,000. Finally, State Street Corp boosted its position in CytomX Therapeutics by 697.1% in the fourth quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock worth $21,900,000 after purchasing an additional 4,495,949 shares during the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Price Performance

CTMX stock opened at $3.60 on Monday. The stock has a market capitalization of $612.67 million, a price-to-earnings ratio of -8.78 and a beta of 2.18. The business’s fifty day moving average price is $4.21 and its two-hundred day moving average price is $4.54. CytomX Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. The firm had revenue of $10.26 million for the quarter, compared to analysts’ expectations of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. Research analysts expect that CytomX Therapeutics will post -0.46 EPS for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.